Releasing the brakes: targeting FcγRIIB on B cells to enhance antibody-dependent lymphoma immunotherapy.
The inhibitory Fcγ receptor modulates therapeutic antibody activity by setting a threshold for effector cell activation and removing antibodies from the tumor cell surface. In this issue of Cancer Cell, Roghanian and colleagues demonstrate that antibodies blocking inhibitory Fcγ receptor function can enhance therapeutic antibody activity to allow optimal tumor cell depletion.